Theravance Biopharma Reports Positive New Data from Multiple Studies of VIBATIV(R) (telavancin) at 2018 ECCMID(TM) Conference

Data from TOUR™ Observational Patient Registry Demonstrate Clinical Response Rates with VIBATIV® (telavancin) Treatment Range from 76.5 - 78.8% for Obese and Elderly Patient Subgroups Additional Study Results Demonstrate VIBATIV to Have 8- to 32-Fol... Biopharmaceuticals Theravance Biopharma, VIBATIV, telavancin
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news